Clear Cell Chondrosarcoma

Clear cell chondrosarcoma is a rare, low-grade malignant cartilage-forming tumour defined by sheets of tumour cells with abundant clear, glycogen-rich cytoplasm, admixed osteoclast-type giant cells and intralesional woven bone formation. It was delineated as a distinct entity by Unni and colleagues at the Mayo Clinic in 1976 and remains recognised as a separate variant in the WHO classification of bone tumours.

Who. It accounts for roughly 1 to 2 percent of chondrosarcomas, so most units see a handful of cases in a career. Peak incidence is in the third to fifth decades, with a male-to-female ratio of about 2 to 3 : 1.

Where. The proximal femur (femoral head and neck) is the commonest site by a wide margin, then the proximal humerus; proximal tibia, distal femur, spine, ribs and craniofacial bones are described but uncommon. The lesion is almost always epiphyseal or epiphyseal-equivalent (apophyses, small round bones), and extension into the metaphysis occurs with growth.

How it behaves. It is conventionally regarded as grade 1 in behaviour: slow growing, locally destructive, with low metastatic propensity. It is not benign. Untreated or inadequately treated disease recurs locally, metastases to lung and to other bones are well documented, sometimes after very long latency, and recurrent tumours may show dedifferentiation to high-grade sarcoma, which carries a poor prognosis.

Macroscopic. Soft to gritty, grey-white to reddish-brown tissue; cystic haemorrhagic areas are common, and gritty foci correspond to woven bone and mineralised cartilage. The lesion abuts and may breach the subchondral plate.

Microscopic. Three features make the diagnosis:

1. Clear cells: sheets and lobules of large, round to polygonal cells with abundant, empty-appearing (glycogen-rich) cytoplasm, sharply defined cell membranes, and central rounded nuclei with fine chromatin and small nucleoli. Mitoses are scarce.
2. Osteoclast-type multinucleated giant cells scattered throughout, which is why it is misread as chondroblastoma or giant cell tumour.
3. Intralesional woven bone: irregular trabeculae of reactive and tumour-derived woven bone within the lesion. A malignant cartilage tumour that forms bone is the feature that clinches it, and also the feature that leads to the erroneous diagnosis of osteosarcoma if the cartilage component is under-sampled.

Low-grade hyaline cartilage lobules are present in most cases, sometimes only focally, alongside secondary aneurysmal bone cyst change and areas indistinguishable from conventional grade 1 chondrosarcoma.

View larger

View larger

Special stains and immunohistochemistry. The panel confirms the lineage and separates the mimics:

• PAS positive, diastase sensitive cytoplasm (glycogen)
• S100 positive, confirming chondroid lineage
• Cytokeratin, EMA, PAX8 and CD10 negative, excluding metastatic clear cell renal carcinoma
• H3K36M immunostain negative; chondroblastoma is positive (H3F3B K36M mutation), which makes this a genuinely useful modern discriminator
• IDH1/IDH2 mutations, characteristic of conventional chondrosarcoma and enchondroma, are generally not a feature of clear cell chondrosarcoma

Stage. Use the Enneking (MSTS) system for surgical staging. This is a low-grade (G1) lesion, usually intracompartmental (T1) unless there is soft tissue extension or joint contamination, and M0, hence Stage IA or IB; Stage III denotes metastatic disease. The AJCC staging for bone sarcoma may also be quoted (grade, size, and presence of skip or distant metastasis).

The package and the meeting. The full staging package is whole-bone MRI with contrast, CT of the lesion, CT chest, bone scan or whole-body MRI, and baseline bloods. Every case is referred to a specialist bone sarcoma unit before any instrumentation and discussed at a specialist bone and soft tissue sarcoma MDT, with a bone tumour pathologist, musculoskeletal radiologist, sarcoma oncologist and orthopaedic oncology surgeon, before any definitive procedure. The consent discussion covers limb salvage versus amputation, implant survivorship, function expectations and the requirement for lifelong follow-up.

The history. Symptom duration is measured in years, not weeks. Median symptom duration commonly exceeds 12 to 24 months, and histories of 5 to 10 years of "groin strain" or "shoulder impingement" are typical and highly characteristic. The pain is deep, aching and activity-related: groin pain radiating to the anterior thigh or knee for proximal femoral lesions, deep shoulder pain with night ache for humeral lesions. It is often initially mechanical and intermittent, then becomes constant and nocturnal as the lesion enlarges.

What else to ask. Pathological fracture through the femoral neck is a recognised presentation and may be the first event, in perhaps 20 to 25 percent of femoral cases. Systemic upset, weight loss and fever are absent, and their presence should redirect towards infection or a different diagnosis. Ask specifically about a previous curettage or "cyst removal" elsewhere: recurrent clear cell chondrosarcoma after mislabelled chondroblastoma is a classic referral.

Examination of the hip. Examination is deliberately unrewarding, and that is part of the teaching point, so perform it systematically. Gait is antalgic, often with a Trendelenburg component from long-standing disuse abductor weakness. A mass is rare and deep femoral head lesions are impalpable; palpate the greater trochanter and anterior joint line for tenderness. For range of motion the patient lies supine, the examiner stabilises the pelvis with one hand on the contralateral ASIS and moves the limb with the other, looking for loss of internal rotation in flexion first. Three tests complete the hip examination:

• FADIR (anterior impingement) test: supine, hip flexed to 90 degrees, then adducted and internally rotated. Reproduction of deep groin pain is positive and means intra-articular or juxta-articular pathology. Femoroacetabular impingement, labral tear and early osteoarthritis give false positives, which is exactly why this test misleads and delays diagnosis for years.
• Log roll: supine, limb extended, the leg rolled internally and externally. Groin pain implies an intra-articular source and is relatively specific because it does not stress soft tissues.
• Straight leg raise against resistance: pain suggests structural weakness of the femoral neck, a red flag for impending fracture.

Examination of the shoulder. Palpate for a proximal humeral fullness; the deltoid may mask a substantial mass. Preserved passive range with a painful active arc suggests reactive rather than structural loss. Assess axillary nerve sensation over the deltoid badge and deltoid contraction, an essential baseline before any proximal humeral resection, and palpate the axilla and supraclavicular fossa for nodes, which are rarely involved but should be documented. Always examine the whole limb and the contralateral side, and record a neurovascular baseline before any intervention.

Red flags in the young adult hip clinic. Any of the following in a patient labelled with FAI, labral tear or "hip dysplasia pain" should trigger cross-sectional imaging:

• Pain unremitting at night and unrelieved by rest
• Symptoms progressing rather than fluctuating over years
• A lytic epiphyseal lucency on any plain film, however small
• Pain out of keeping with the modest cam or pincer morphology seen
• Failure to improve after appropriate physiotherapy or after a hip arthroscopy

Age is the first discriminator. Chondroblastoma is a lesion of the open physis, typically 10 to 20 years, so an epiphyseal lesion in a skeletally mature adult, particularly if larger than 3 to 4 cm with a years-long history, must be assumed malignant until biopsy proves otherwise. Both lesions are epiphyseal and both contain giant cells, so neither of those features settles anything; the table below is what does.

The rest of the adult epiphyseal differential. Once those three are weighed, the remaining lesions are separated by site, matrix and a few stains.

Timing. All imaging is completed before biopsy, so that the tract can be sited for excision en bloc with the specimen and the needle directed at the right part of the lesion.

Technique. The preferred method is image-guided (CT or ultrasound) core needle biopsy, taking multiple cores from the solid enhancing component identified on post-gadolinium MRI and avoiding cystic, necrotic or aneurysmal areas. If core sampling is non-diagnostic, proceed to open incisional biopsy with meticulous haemostasis and no drains through separate stab incisions (or place the drain exit in line with the incision so it can be excised). Send tissue for histology, microbiology and fresh tissue for molecular studies where available.

The tract. It runs longitudinally, in line with the planned incision, through a single compartment. For the proximal femur that means an anterolateral tract in line with a lateral or anterolateral approach; mark the entry point with ink or a suture and record it in the operation note and imaging report so it can be excised en bloc. Avoid transgluteal tracts, crossing the hip joint capsule unnecessarily, traversing neurovascular bundles, and traversing the deltoid in multiple planes at the shoulder. A transgluteal or multi-compartment hip tract can force a hemipelvectomy that a correctly placed anterolateral tract would have avoided.

Pitfalls. Three recur:

• Sampling only the secondary aneurysmal bone cyst component and reporting "aneurysmal bone cyst". Always correlate with the enhancing solid nodule on MRI.
• A frozen section report of "chondroblastoma-like lesion with giant cells" leading directly to curettage on the same list. Never proceed to definitive treatment on frozen section for an adult epiphyseal cartilage lesion.
• Failure to obtain a second opinion from a specialist bone tumour pathologist. This variant is rare and the misdiagnosis rate outside referral centres is meaningful.

View larger

The central rule. Once clear cell chondrosarcoma is diagnosed, intralesional treatment is inadequate. Wide en-bloc resection with a cuff of normal tissue on all surfaces, reconstructed with an endoprosthesis or osteoarticular allograft, is the treatment of choice and is generally curative. No curettage, no burring, no cement or adjuvant packing as definitive care: intralesional curettage contaminates the joint and soft tissues, produces local recurrence rates several-fold higher than wide resection, risks dedifferentiation, and can convert a curable low-grade tumour into an unsalvageable one.

The decision map. The situation in front of you chooses the operation:

Adjuvants do not rescue a poor margin. Chemotherapy is ineffective: cartilage matrix, a low mitotic rate and poor drug penetration, and there is no evidence of survival benefit in low-grade cartilage malignancy. Reserve consideration for dedifferentiated recurrence, where a high-grade sarcoma protocol may be discussed. Radiotherapy is ineffective as primary treatment and is reserved for unresectable disease, close or positive margins where re-resection is impossible, or palliation; proton or carbon-ion therapy is used in some centres for axial unresectable chondrosarcoma. Surgery is the only reliably curative modality, and that is worth saying plainly in the viva.

Each recurring hazard is mapped here to its mechanism, its prevention and its salvage.

What decides the outcome. Surgical margin is the dominant modifiable factor: wide resection yields long-term disease-free survival in the great majority, and intralesional treatment produces high recurrence. Metastasis at presentation, large tumour size, axial location and dedifferentiation in recurrent disease predict worse survival. Overall survival after adequate wide resection is commonly reported in excess of 85 percent at 5 to 10 years in collected series, but the survival curve does not plateau, because late events occur.

Why the follow-up never ends. Recurrence and pulmonary or skeletal metastasis are documented 10 to 20 years and beyond after resection, so five-year clearance means nothing here and the patient is committed to lifelong imaging surveillance. The schedule below is representative; adapt it to unit protocol.

Related pages. The lesion this is mistaken for, and the error that follows: Chondroblastoma is the epiphyseal tumour of the skeletally IMMATURE patient that shares the giant cells and the location - the H3K36M stain separates them - and curetting a clear cell chondrosarcoma as though it were one is the defining harm on this page. Giant Cell Tumour of Bone carries the other histone mutation and completes the epiphyseal giant-cell-rich differential, with Epiphyseal Bone Lesion as the regional approach. The cartilage family: Chondrosarcoma for the conventional tumour whose areas appear in about half of these cases, Enchondroma for the benign end of the spectrum, and Dedifferentiated Chondrosarcoma for what a recurrence must be re-biopsied to exclude. Getting the diagnosis without causing harm: Biopsy Principles and Techniques is the practical expression of the Mankin data, and Limb Salvage Surgery Principles with Megaprosthesis Reconstruction covers the reconstruction after wide resection of the proximal femur.

Global epidemiology and access. Clear cell chondrosarcoma is rare and geographically uniform in distribution; there is no established ethnic or regional predilection. What varies enormously is time to diagnosis and access to a sarcoma centre. In high-income systems with established referral pathways, most patients reach a bone tumour unit before any surgical intervention. In settings with limited MRI access and no centralised sarcoma service, the most common pathway is inadvertent curettage of a presumed benign cyst, followed by late referral with contaminated tissue planes.

Society guidance that genuinely addresses this tumour

Registry and reconstruction evidence. Because tumour endoprostheses are implanted in small numbers, the informative datasets are national and international bone tumour registries and implant registries (for example the Australian Orthopaedic Association National Joint Replacement Registry and the National Joint Registry, both of which capture tumour prostheses, alongside dedicated sarcoma registries such as those of the Rizzoli Institute and the Netherlands Committee on Bone Tumours). Consistent messages: infection and aseptic loosening dominate late failure; revision burden accumulates in young patients over decades; and cumulative implant survivorship falls steadily beyond ten years, which is precisely the horizon relevant to a 30-year-old with a curable low-grade tumour. Consent must reflect a lifetime of revision surgery, not just the index operation.

Practice variation by resource setting

• Where modular tumour endoprostheses are unavailable, osteoarticular allograft, allograft-prosthetic composite, resection-arthrodesis or resection without reconstruction are legitimate reconstructions; the oncological principle (wide margin) is not negotiable, the reconstruction is.
• Where MRI is limited, whole-bone plain radiography plus CT with careful clinical correlation should still identify the epiphyseal lesion; the imperative is referral before intervention.
• Telepathology and international second-opinion networks materially reduce misdiagnosis of this rare variant and should be used where local specialist bone pathology is unavailable.

1. Is intralesional treatment ever acceptable? A minority argue that a very small, entirely intraosseous, radiologically contained lesion could be treated by meticulous extended curettage with adjuvants, preserving a native hip in a young adult. The counter-argument is that recurrence rates after intralesional treatment are unequivocally higher in every published series, recurrences may dedifferentiate, and the tumour is curable with wide resection. Current consensus: wide resection is standard; intralesional treatment should be an exceptional, MDT-documented decision.

2. Endoprosthesis versus osteoarticular allograft in the proximal femur and humerus. Endoprostheses give immediate stability and reliable early function but accrue infection, loosening and revision over decades. Allografts offer soft tissue reattachment and bone stock but carry fracture, non-union, resorption and joint degeneration. Allograft-prosthetic composites attempt to combine both. No randomised data exist; choice is centre- and patient-dependent.

3. Reverse total shoulder after proximal humeral resection. Improves active elevation compared with a hemiarthroplasty-type endoprosthesis, but requires an intact deltoid, functioning axillary nerve and preserved glenoid — conditions frequently not met after an oncological resection. Selection, not technique, determines the result.

4. Duration and intensity of surveillance. There is no evidence-based schedule. Late metastasis is well documented, but the yield of annual chest CT at 15 or 20 years and the cumulative radiation burden in a young patient are unquantified. Many units transition to lower-dose or lower-frequency imaging combined with a strong safety-netting message.

5. Role of particle (proton/carbon-ion) radiotherapy. Increasingly used for unresectable axial chondrosarcoma. Its role in clear cell chondrosarcoma specifically is essentially undefined given the rarity and the usually resectable appendicular location.

6. Molecular characterisation. Unlike conventional chondrosarcoma (IDH-mutant in a large proportion), clear cell chondrosarcoma lacks a defining driver. Whether it is a distinct entity biologically or a morphological pattern remains an open question, and there is currently no targeted therapy.